{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:32:03Z","timestamp":1768530723771,"version":"3.49.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12933-018-0753-5","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T06:50:07Z","timestamp":1533192607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-363X","authenticated-orcid":false,"given":"Gilberto","family":"Velho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Ragot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"El Boustany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Jean","family":"Saulnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Fraty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Mohammedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Fumeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Potier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Marre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"9","key":"753_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"SR Seshasai","year":"2011","unstructured":"Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829\u201341.","journal-title":"N Engl J Med"},{"issue":"13","key":"753_CR2","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1001\/archinte.164.13.1422","volume":"164","author":"T Almdal","year":"2004","unstructured":"Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20\u00a0years of follow-up. Arch Intern Med. 2004;164(13):1422\u20136.","journal-title":"Arch Intern Med"},{"issue":"4","key":"753_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-005-0120-4","volume":"49","author":"SS Soedamah-Muthu","year":"2006","unstructured":"Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992\u20131999. Diabetologia. 2006;49(4):660\u20136.","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"753_CR4","first-page":"S79","volume":"27","author":"ME Molitch","year":"2004","unstructured":"Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW, American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27(Suppl. 1):S79\u201383.","journal-title":"Diabetes Care."},{"issue":"8","key":"753_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/archinte.160.8.1093","volume":"160","author":"CT Valmadrid","year":"2000","unstructured":"Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093\u2013100.","journal-title":"Arch Intern Med"},{"issue":"4","key":"753_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/TP.0b013e3181b11ae4","volume":"88","author":"E Meijer","year":"2009","unstructured":"Meijer E, Bakker SJ, de Jong PE, van der Heide JJH, Son WJ, Struck J, Lems SP, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation. 2009;88(4):561\u20137.","journal-title":"Transplantation"},{"issue":"1","key":"753_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ki.2009.397","volume":"77","author":"E Meijer","year":"2010","unstructured":"Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int. 2010;77(1):29\u201336.","journal-title":"Kidney Int"},{"issue":"25","key":"753_CR8","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, Tempo Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med"},{"issue":"4","key":"753_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrneph.2013.22","volume":"9","author":"L Bankir","year":"2013","unstructured":"Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol. 2013;9(4):223\u201339.","journal-title":"Nat Rev Nephrol."},{"key":"753_CR10","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.2337\/dc13-0683","volume":"36","author":"G Velho","year":"2013","unstructured":"Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care. 2013;36:3639\u201345.","journal-title":"Diabetes Care"},{"issue":"2","key":"753_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000439061","volume":"42","author":"R Roussel","year":"2015","unstructured":"Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, Fumeron F, Mohammedi K, Balkau B, Marre M, Bankir L, Velho G. Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. study. Am J Nephrol. 2015;42(2):107\u201314.","journal-title":"Am J Nephrol"},{"issue":"1","key":"753_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000447522","volume":"44","author":"I Tasevska","year":"2016","unstructured":"Tasevska I, Enhorning S, Christensson A, Persson M, Nilsson PM, Melander O. Increased levels of copeptin, a surrogate marker of arginine vasopressin, are associated with an increased risk of chronic kidney disease in a general population. Am J Nephrol. 2016;44(1):22\u20138.","journal-title":"Am J Nephrol"},{"issue":"12","key":"753_CR13","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.2337\/dc16-1003","volume":"39","author":"G Velho","year":"2016","unstructured":"Velho G, El Boustany R, Lefevre G, Mohammedi K, Fumeron F, Potier L, Bankir L, Bouby N, Hadjadj S, Marre M, Roussel R. Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes. Diabetes Care. 2016;39(12):2288\u201395.","journal-title":"Diabetes Care"},{"issue":"4","key":"753_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/joim.12654","volume":"282","author":"WF Clark","year":"2017","unstructured":"Clark WF, Devuyst O, Roussel R. The vasopressin system: new insights for patients with kidney diseases: epidemiological evidence and therapeutic perspectives. J Intern Med. 2017;282(4):310\u201321.","journal-title":"J Intern Med"},{"key":"753_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jdiacomp.2017.04.005","volume":"31","author":"R Boustany El","year":"2017","unstructured":"El Boustany R, Taveau C, Chollet C, Velho G, Bankir L, Alhenc-Gelas F, Roussel R, Bouby N. Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes. J Diabetes Complications. 2017;31:929\u201332.","journal-title":"J Diabetes Complications."},{"issue":"4","key":"753_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/MNH.0000000000000335","volume":"26","author":"R Roussel","year":"2017","unstructured":"Roussel R, Velho G, Bankir L. Vasopressin and diabetic nephropathy. Curr Opin Nephrol Hypertens. 2017;26(4):311\u20138.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"13","key":"753_CR17","doi-asserted-by":"publisher","first-page":"e121479","DOI":"10.1172\/jci.insight.121479","volume":"3","author":"R Boustany El","year":"2018","unstructured":"El Boustany R, Tasevska I, Meijer E, Kieneker LM, Enh\u00f6rning S, Lef\u00e8vre G, Mohammedi K, Marre M, Fumeron F, Balkau B, Bouby N, Bankir L, Bakker SJL, Roussel R, Melander O, Gansevoort RT, Velho G. Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population. JCI Insight. 2018;3(13):e121479.","journal-title":"JCI Insight."},{"issue":"4","key":"753_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ahj.2014.11.020","volume":"169","author":"S Enhorning","year":"2015","unstructured":"Enhorning S, Hedblad B, Nilsson PM, Engstrom G, Melander O. Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J. 2015;169(4):549\u201356.","journal-title":"Am Heart J."},{"issue":"2","key":"753_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/heartjnl-2015-308183","volume":"102","author":"I Tasevska","year":"2016","unstructured":"Tasevska I, Enhorning S, Persson M, Nilsson PM, Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart. 2016;102(2):127\u201332.","journal-title":"Heart"},{"issue":"9","key":"753_CR20","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1007\/s00125-016-4011-7","volume":"59","author":"SG Wannamethee","year":"2016","unstructured":"Wannamethee SG, Welsh P, Lennon L, Papacosta O, Whincup PH, Sattar N. Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study. Diabetologia. 2016;59(9):1904\u201312.","journal-title":"Diabetologia"},{"issue":"4","key":"753_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-2456(00)00060-X","volume":"21","author":"M Lievre","year":"2000","unstructured":"Lievre M, Marre M, Chatellier G, Plouin P, Reglier J, Richardson L, Bugnard F, Vasmant D. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. Control Clin Trials. 2000;21(4):383\u201396.","journal-title":"Control Clin Trials."},{"issue":"7438","key":"753_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","volume":"328","author":"M Marre","year":"2004","unstructured":"Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004;328(7438):495.","journal-title":"BMJ"},{"issue":"9","key":"753_CR23","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.2337\/dc07-2079","volume":"31","author":"S Hadjadj","year":"2008","unstructured":"Hadjadj S, Fumeron F, Roussel R, Saulnier PJ, Gallois Y, Ankotche A, Travert F, Abi Khalil C, Miot A, Alhenc-Gelas F, Lievre M, Marre M. Prognostic value of the insertion\/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. Diabetes Care. 2008;31(9):1847\u201352.","journal-title":"Diabetes Care"},{"issue":"10","key":"753_CR24","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2337\/dc11-2468","volume":"35","author":"A Miot","year":"2012","unstructured":"Miot A, Ragot S, Hammi W, Saulnier PJ, Sosner P, Piguel X, Torremocha F, Marechaud R, Hadjadj S. Prognostic value of resting heart rate on cardiovascular and renal outcomes in type 2 diabetic patients: a competing risk analysis in a prospective cohort. Diabetes Care. 2012;35(10):2069\u201375.","journal-title":"Diabetes Care"},{"issue":"5","key":"753_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.2337\/dc13-2580","volume":"37","author":"PJ Saulnier","year":"2014","unstructured":"Saulnier PJ, Gand E, Ragot S, Ducrocq G, Halimi JM, Hulin-Delmotte C, Llaty P, Montaigne D, Rigalleau V, Roussel R, Velho G, Sosner P, Zaoui P, Hadjadj S, Group SS. Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort. Diabetes Care. 2014;37(5):1425\u201331.","journal-title":"Diabetes Care"},{"issue":"14","key":"753_CR26","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. Guidelines ESCCfP. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787\u2013847.","journal-title":"Eur Heart J"},{"issue":"9","key":"753_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. CKD-EPI group. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"1","key":"753_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1\u2013150.","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"753_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","volume":"52","author":"NG Morgenthaler","year":"2006","unstructured":"Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112\u20139.","journal-title":"Clin Chem"},{"issue":"1","key":"753_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1210\/jc.2008-1426","volume":"94","author":"W Fenske","year":"2009","unstructured":"Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009;94(1):123\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"753_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1042\/CS20080140","volume":"116","author":"SS Bhandari","year":"2009","unstructured":"Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009;116(3):257\u201363.","journal-title":"Clin Sci (Lond)."},{"issue":"7","key":"753_CR32","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00125-012-2545-x","volume":"55","author":"A Abbasi","year":"2012","unstructured":"Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2012;55(7):1963\u201370.","journal-title":"Diabetologia"},{"key":"753_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2012.1088","author":"S Enhorning","year":"2012","unstructured":"Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes. 2012. \n                    https:\/\/doi.org\/10.1038\/ijo.2012.1088\n                    \n                  .","journal-title":"Int J Obes."},{"key":"753_CR34","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1210\/jc.2014-2295","volume":"99","author":"R Roussel","year":"2014","unstructured":"Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG, the D.E.S.I.R. Study Group. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab. 2014;99:4656\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"753_CR35","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1210\/jc.2016-1113","volume":"101","author":"R Roussel","year":"2016","unstructured":"Roussel R, El Boustany R, Bouby N, Potier L, Fumeron F, Mohammedi K, Balkau B, Tichet J, Bankir L, Marre M, Velho G. Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community. J Clin Endocrinol Metab. 2016;101:2432\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"753_CR36","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1007\/s00125-013-2922-0","volume":"56","author":"WE Boertien","year":"2013","unstructured":"Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, Groenier KH, Struck J, de Jong PE, Bilo HJ, Kleefstra N, Gansevoort RT. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia. 2013;56(8):1680\u20138.","journal-title":"Diabetologia"},{"issue":"4","key":"753_CR37","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1681\/ASN.2010070691","volume":"22","author":"W Fenske","year":"2011","unstructured":"Fenske W, Wanner C, Allolio B, Drechsler C, Blouin K, Lilienthal J, Krane V. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol. 2011;22(4):782\u201390.","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"753_CR38","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1212\/WNL.0000000000003937","volume":"88","author":"WJ Tu","year":"2017","unstructured":"Tu WJ, Ma GZ, Ni Y, Hu XS, Luo DZ, Zeng XW, Liu Q, Xu T, Yu L, Wu B. Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke. Neurology. 2017;88(20):1899\u2013905.","journal-title":"Neurology."},{"issue":"5","key":"753_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1373\/clinchem.2016.266254","volume":"63","author":"V Krane","year":"2017","unstructured":"Krane V, Genser B, Kleber ME, Drechsler C, Marz W, Delgado G, Allolio B, Wanner C, Fenske W. Copeptin associates with cause-specific mortality in patients with impaired renal function: results from the LURIC and the 4D study. Clin Chem. 2017;63(5):997\u20131007.","journal-title":"Clin Chem"},{"key":"753_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-017-1595-8","author":"S Enhorning","year":"2017","unstructured":"Enhorning S, Tasevska I, Roussel R, Bouby N, Persson M, Burri P, Bankir L, Melander O. Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans. Eur J Nutr. 2017. \n                    https:\/\/doi.org\/10.1007\/s00394-017-1595-8\n                    \n                  .","journal-title":"Eur J Nutr."},{"key":"753_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-017-1471-6","author":"G Lemetais","year":"2017","unstructured":"Lemetais G, Melander O, Vecchio M, Bottin JH, Enhorning S, Perrier ET. Effect of increased water intake on plasma copeptin in healthy adults. Eur J Nutr. 2017. \n                    https:\/\/doi.org\/10.1007\/s00394-017-1471-6\n                    \n                  .","journal-title":"Eur J Nutr."},{"issue":"11","key":"753_CR42","doi-asserted-by":"publisher","first-page":"e008634","DOI":"10.1136\/bmjopen-2015-008634","volume":"5","author":"JM Sontrop","year":"2015","unstructured":"Sontrop JM, Huang SH, Garg AX, Moist L, House AA, Gallo K, Clark WF. Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial. BMJ Open. 2015;5(11):e008634.","journal-title":"BMJ Open"},{"issue":"18","key":"753_CR43","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2018.4930","volume":"319","author":"WF Clark","year":"2018","unstructured":"Clark WF, Sontrop JM, Huang S-H, Gallo K, Moist L, House AA, Cuerden MS, Weir MA, Bagga A, Brimble S, Burke A, Muirhead N, Pandeya S, Garg AX. Effect of coaching to increase water intake on kidney function decline in adults with chronic kidney disease. The CKD WIT randomized clinical trial. JAMA. 2018;319(18):1870\u20139.","journal-title":"JAMA"},{"issue":"9889","key":"753_CR44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339\u201352.","journal-title":"Lancet"},{"issue":"1","key":"753_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-016-0420-7","volume":"15","author":"Y Peng","year":"2016","unstructured":"Peng Y, Wang H, Chen F, Huang FY, Xia TL, Liao YB, Chai H, Wang PJ, Zuo ZL, Liu W, Zhang C, Li YJ, Gui YY, Chen M, Huang DJ. The influence of body composition on renal function in patients with coronary artery disease and its prognostic significance: a retrospective cohort study. Cardiovasc Diabetol. 2016;15(1):106.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"753_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12933-017-0618-3","volume":"16","author":"K Kakuta","year":"2017","unstructured":"Kakuta K, Dohi K, Miyoshi M, Yamanaka T, Kawamura M, Masuda J, Kurita T, Ogura T, Yamada N, Sumida Y, Ito M. Impact of renal function on the underlying pathophysiology of coronary plaque composition in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):131.","journal-title":"Cardiovasc Diabetol."},{"key":"753_CR47","first-page":"19","volume":"2","author":"GP Mavani","year":"2015","unstructured":"Mavani GP, DeVita MV, Michelis MF. A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin. Front Med. 2015;2:19.","journal-title":"Front Med."},{"issue":"4","key":"753_CR48","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","volume":"92","author":"TA Koshimizu","year":"2012","unstructured":"Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813\u201364.","journal-title":"Physiol Rev"},{"issue":"2","key":"753_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1042\/bj1720311","volume":"172","author":"DA Hems","year":"1978","unstructured":"Hems DA, Rodrigues LM, Whitton PD. Rapid stimulation by vasopressin, oxytocin and angiotensin II of glycogen degradation in hepatocyte suspensions. Biochem J. 1978;172(2):311\u20137.","journal-title":"Biochem J."},{"issue":"3","key":"753_CR50","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1042\/bj1760893","volume":"176","author":"PD Whitton","year":"1978","unstructured":"Whitton PD, Rodrigues LM, Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J. 1978;176(3):893\u20138.","journal-title":"Biochem J."},{"issue":"5","key":"753_CR51","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00125-015-3496-9","volume":"58","author":"C Taveau","year":"2015","unstructured":"Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, Hainault I, Enhorning S, Velho G, Roussel R, Bankir L, Melander O, Bouby N. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia. 2015;58(5):1081\u201390.","journal-title":"Diabetologia"},{"issue":"9","key":"753_CR52","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1053\/meta.2002.34052","volume":"51","author":"EA Abu-Basha","year":"2002","unstructured":"Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism. 2002;51(9):1184\u201390.","journal-title":"Metabolism."},{"issue":"5881","key":"753_CR53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/299355a0","volume":"299","author":"GE Gillies","year":"1982","unstructured":"Gillies GE, Linton EA, Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature. 1982;299(5881):355\u20137.","journal-title":"Nature"},{"issue":"6","key":"753_CR54","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/cc2337","volume":"7","author":"CL Holmes","year":"2003","unstructured":"Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1\u2013receptor physiology. Crit Care. 2003;7(6):427\u201334.","journal-title":"Crit Care"},{"issue":"4","key":"753_CR55","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/joim.12649","volume":"282","author":"K Nakamura","year":"2017","unstructured":"Nakamura K, Velho G, Bouby N. Vasopressin and metabolic disorders: translation from experimental models to clinical use. J Intern Med. 2017;282(4):298\u2013309.","journal-title":"J Intern Med"},{"issue":"1","key":"753_CR56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0304-4165(75)90294-9","volume":"411","author":"DA Hems","year":"1975","unstructured":"Hems DA, Whitton PD, Ma GY. Metabolic actions of vasopressin, glucagon and adrenalin in the intact rat. Biochim Biophys Acta. 1975;411(1):155\u201364.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"753_CR57","doi-asserted-by":"publisher","first-page":"E127","DOI":"10.1152\/ajpendo.00269.2016","volume":"312","author":"C Taveau","year":"2017","unstructured":"Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N. Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1A receptors. Am J Physiol Endocrinol Metab. 2017;312(3):E127\u201335.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"753_CR58","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2265.1985.tb00145.x","volume":"22","author":"BA Spruce","year":"1985","unstructured":"Spruce BA, McCulloch AJ, Burd J, Orskov H, Heaton A, Baylis PH, Alberti KG. The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol. 1985;22:463\u20138.","journal-title":"Clin Endocrinol"},{"issue":"7","key":"753_CR59","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1210\/jc.2008-2278","volume":"94","author":"U Saleem","year":"2009","unstructured":"Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, Kullo IJ. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab. 2009;94(7):2558\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"753_CR60","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1161\/CIRCULATIONAHA.109.909663","volume":"121","author":"S Enhorning","year":"2010","unstructured":"Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121:2102\u20138.","journal-title":"Circulation"},{"issue":"1","key":"753_CR61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00592-014-0609-8","volume":"52","author":"C Then","year":"2015","unstructured":"Then C, Kowall B, Lechner A, Meisinger C, Heier M, Koenig W, Peters A, Rathmann W, Seissler J. Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study. Acta Diabetol. 2015;52(1):103\u201312.","journal-title":"Acta Diabetol"},{"issue":"9","key":"753_CR62","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1210\/JC.2015-2362","volume":"100","author":"SG Wannamethee","year":"2015","unstructured":"Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab. 2015;100(9):3332\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"753_CR63","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ekir.2017.01.006","volume":"2","author":"EM Ettema","year":"2017","unstructured":"Ettema EM, Heida J, Casteleijn NF, Boesten L, Westerhuis R, Gaillard C, Gansevoort RT, Franssen CFM, Zittema D. The effect of renal function and hemodialysis treatment on plasma vasopressin and copeptin levels. Kidney Int Rep. 2017;2(3):410\u20139.","journal-title":"Kidney Int Rep."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-018-0753-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T19:06:51Z","timestamp":1564686411000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0753-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1186\/s12933-018-0753-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]},"assertion":[{"value":"9 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"110"}}